Dr. Binder served as Senior Vice President of Research and Development and Chief Technology Officer of INOVA Diagnostics until 2015. Dr. Binder was one of the five original founders of INOVA Diagnostics, and served as the company’s President as well as Director of Research for twenty years. During this period, INOVA became the world leader in autoimmune disease diagnostics. INOVA obtained FDA approval for over 100 diagnostic assays, including the first automated serological tests for celiac disease. These assays include the anti-IgA tissue transglutaminase (tTg) and deamidated gliadin peptide (DGP) tests which currently form the cornerstone of screening for celiac disease. In 2008, INOVA was acquired by the Werfen group, a large international medical company based in Barcelona.
Prior to founding INOVA, Dr. Binder served as Director of Research for Behring Diagnostics, where he led a group responsible for the development and commercialization of some of the first blood test kits for diagnosis of systemic lupus erythematosus and other connective tissues diseases.
Dr. Binder received his PhD in medical microbiology from the State University of New York at Buffalo, where his research interests centered on immunopathology and autoimmune diseases. He completed post-doctoral studies at the University of California San Francisco Medical Center and VA Hospital,
Peter H.R. Green, MD serves as a Professor of Clinical Medicine and Director of the Celiac Disease Center of Columbia University in New York City. Dr. Green has been at Columbia University Medical Center in New York since completing his Fellowship. Dr. Green has previously served as President of the New York Society of Gastrointestinal Endoscopy and remains on the Council of the Society. He is one of the few physicians in the United States with an intense clinical and academic interest and expertise in celiac disease. As a result of the need for a coordinated approach for the medical care of patients with celiac disease, Dr. Green established the Celiac Disease Center at Columbia University. He is a Fellow of the Royal Australasian College of Physicians and the American College of Gastroenterology as well as a Member of the American Gastroenterological Association and American Society of Gastrointestinal Endoscopy.
Dr. Green attended medical school at University of Sydney, Australia. His fellowships were completed at Royal North Shore Hospital in Sydney and at the Beth Israel Hospital, Harvard Medical School. He is a recipient of the AGA Foundation Mentors Research Scholar Award and the ASGE Master Endoscopist Award.
Bana Jabri, MD, PhD, is a Professor in the Departments of Medicine, Pathology and Pediatrics at the University of Chicago Medical Center, and is a member of the Committee on Immunology. She is also Co-Director of the University of Chicago Digestive Disease Research Core Center. Dr. Jabri is one of the leading researchers of celiac disease in the world and has directed the research team at University of Chicago Celiac Center since 1999. With her leadership, the University of Chicago Celiac Disease Center Research continues to make great strides in determining what triggers the abnormal reaction to gluten in celiac disease.
Previously, Dr. Jabri worked in research at Princeton University, after which she joined the University of Chicago. During this period, she served as Ad-Hoc reviewer for the Celiac Program Project at the National Institutes of Health (NIH) and for the Crohn’s and Colitis Foundation. She has co-authored numerous articles in peer-reviewed publications on celiac disease and other digestive disorders. One of Dr. Jabri’s current research focuses is on discovering markers that can identify gluten sensitivity before antibodies to gluten are present. She has received grant support for this work from the NIH.
Dr. Jabri completed her PhD in immunology at the University Paris, VII. She received her MD from the Institut Pasteur, Paris and completed her residency in pediatric gastroenterology at the Assistance Publique Hopitaux de Paris.
Dr. Lundin serves as Consultant in the Department of Medicine and Centre for Immune Regulation, a Norwegian Research Council and FOCIS Centre of Excellence at the Rikshospitalet Medical Center. He is a recognized authority on celiac sprue and has authored many scientific publications on the subject. Dr. Lundin’s research group is focused on immunogenetics and immunopathogenesis of celiac sprue.
Dr. Lundin received his Medical and Doctorate degrees at the University of Oslo.
Professor Maki is a pediatric gastroenterologist and full Professor of Pediatrics at the University of Tampere in Finland. He is Chief Physician in the Department of Paediatrics, Tampere University Hospital. After completing his PhD, he began his research into gluten-induced disease, in particular, celiac disease. Professor Maki now leads a multidisciplinary research team at the University of Tampere. He has published over 200 scientific papers on celiac disease.
Professor Maki is one of the innovative opinion leaders in the field of celiac disease worldwide. More than two decades ago, he joined the Finnish Coeliac Society. His research has been inspired by the needs of the celiac sufferers. The outcome of his group’s research is the understanding of the broad clinical spectrum of celiac disease both in children and adults. He has pioneered the correct use of serologic biomarker tests, and has invented a rapid point of care test for case finding in primary practice. Increasing celiac disease awareness in Finland has led to a 20-fold increase in the number of adults with diagnosed celiac disease. Professor Maki’s academic group is collaborating worldwide with other scientific groups, patient organizations, and also with government and industry groups.
Professor Maki was elected President of the National Finnish Celiac Society, and he remains the Chairman of the Scientific Advisory Board. Professor Maki is a permanent member of the Finnish Academy of Science and Letters. The President of Finland has granted him the honor of Knight, First Class, of the Order of the White Rose of Finland in 2006.
Professor Maki received his PhD from the University of Tampere and his MD from the University of Turku.
Professor Murray serves as a Gastroenterologist in the Division of Gastroenterology and Hepatology and a Professor of Medicine at the Mayo Clinic, Rochester Minnesota. There, he runs the celiac disease research and clinical program that focuses on epidemiology, complications and mouse models of gluten sensitivity. He serves as a Consultant to several companies and has clinical experience as well as broad experience with clinical trials. He is an Associate Editor of Clinical Gastroenterology and Hepatology as well as an expert reviewer for many scientific journals. Prior to joining the Mayo Clinic, he founded a celiac disease clinic at the University of Iowa. He has published over 100 scientific articles and has several patents on novel devices for the treatment of GI disorders. He has a large clinical practice focused largely on celiac disease and has been elected to the Best Doctors in America from 2001 to 2006.
Professor Murray received his MB BCh/BAO and MD from the National University of Ireland, Galway and DCH – (Diploma in Child Health) from National University of Ireland, University College of Dublin and completed his fellowship in Gastroenterology and Hepatology from the University of Iowa.
Ludvig M. Sollid, MD, PhD, is the Director of the Centre for Immune Regulation, Oslo, Norway, which is a Research Council of Norway and FOCIS (Federation of Clinical Immunology Societies) center of excellence. He is also a Professor at the University of Oslo and a Senior Consultant at the Oslo University Hospital – Rikshospitalet. He is an internationally recognized authority on celiac disease. His research group has made important contributions to the understanding of the molecular basis of celiac disease, in particular the association between the HLA-DQ2 genes and celiac disease in 1989, the existence of gluten reactive (HLA-DQ2 restricted) T cells in the celiac intestinal lesion in 1993, and role of the primary auto-antigen, tissue transglutaminase, in celiac disease in 1998.
Professor Sollid is the recipient of several research awards including the Research Council of Norway’s Møbius Prize for Outstanding Research (Oslo, 2006), the Warren Prize for Excellence in Celiac Disease Research (San Diego, 2007), the Rank Prize in Nutrition (London, 2010) and the UEG Research Prize (Amsterdam, 2012). Currently, his laboratory investigates the mechanisms for association of MHC molecules with disease and the involvement of T and B cells in the pathogenesis of celiac disease.
Professor Sollid received his MD and PhD from the University of Oslo.
Dr. Tye-Din is a gastroenterologist, celiac disease researcher, and has been closely associated with the development of Nexvax2®. Dr. Tye-Din’s doctoral research based at The Walter and Eliza Hall Institute in Melbourne, studied the impact of gluten on the immune system in coeliac disease and has been published in several highly-regarded peer-reviewed medical journals. This research has generated the first comprehensive understanding of the toxicity of gluten in wheat, rye, barley, and oats, and has enabled the rational design of peptide-based immunotherapy, Nexvax2®, and functional tests to monitor and diagnose celiac disease. Dr. Tye-Din manages patients with celiac disease in specialty clinics at The Royal Melbourne Hospital and at Box Hill Hospital. Dr. Tye-Din is a member of the Coeliac Society of Australia’s Clinical Advisory Committee, and he works closely with support groups to promote better awareness, management, and research in celiac disease. Dr. Tye-Din is engaged in regular presentations to general practitioners, physicians, dietitians and the general public.
Dr. Tye-Din graduated in medicine and received his doctorate from the University of Melbourne. He is a Fellow of the Royal Australasian College of Physicians and is a specialist in gastroenterology.